SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19Julian Braun, Andreas Thiel, Stefan Hippenstiel et al.|Nature|2020Cited by 1.4k
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster ModelJakob Kreye, Harald Prüß, S. Momsen Reincke et al.|Cell|2020Cited by 387
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trialAlexander P. J. Vlaar, Diederik van de Beek, Sanne de Bruin et al.|The Lancet Rheumatology|2020Cited by 199
Presence of SARS-CoV-2-reactive T cells in COVID-19 patients and healthy donorsJulian Braun, Andreas Thiel, Lucie Loyal et al.|medRxiv|2020Cited by 178
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialAlexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al.|The Lancet Respiratory Medicine|2022Cited by 143